NCT04720859 (CANA-PHH-RYGB) is a NA clinical trial of Canagliflozin 300 MG Oral Tablet in Postprandial Hypoglycemia, sponsored by Hospital Universitari Vall d'Hebron Research Institute.

Who is sponsoring NCT04720859?

NCT04720859 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What drugs are being tested in NCT04720859?

Interventions in NCT04720859: Canagliflozin 300 MG Oral Tablet.

What condition does NCT04720859 study?

NCT04720859 studies Postprandial Hypoglycemia.

Is NCT04720859 still recruiting?

NCT04720859 is currently status unknown. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT04720859: CANA-PHH-RYGB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

Status unknown NA Last updated 29 January 2021

What this trial tests

NA trial testing Canagliflozin 300 MG Oral Tablet in Postprandial Hypoglycemia in 40 participants. Status unknown.

Timeline

5 January 2018

Primary endpoint
20 December 2019

31 December 2022

Quick facts

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	5 January 2018
Primary completion	20 December 2019
Estimated completion	31 December 2022
Sites	1 location across Spain

Drugs / interventions tested

Canagliflozin 300 MG Oral Tablet

Conditions studied

Postprandial Hypoglycemia — all drugs for Postprandial Hypoglycemia →

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

Adults 18 to 60, any sex, with Postprandial Hypoglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Roux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Recent data suggested an increase in intestinal SGLT1 after RYGB. However, there are no data on the inhibition of SLGT1 to prevent PHH in patients with prior RYBG. Objectives: To evaluate in patients that present PHH after RYGB: a) the effect of canagliflozin 300mg on the response to 100g glucose overload (OGTT); b) the pancreatic response after intra-arterial calcium stimulation. Material and methods: Prospective pilot study, including patients with PHH after RYGB, matched by age and gender with healthy controls. Basal OGTT and after 2-weeks of daily 300mg of canagliflozin will be performed. In addition, venous sampling after intra-arterial calcium stimulation of the pancreas will be performed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review.
Rossi A, Rutten MGS, van Dijk TH, Bakker BM, et al · · 2022 · cited 6× · PMID 35789807 · DOI 10.3389/fendo.2022.858832

Verify or expand the search:

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04720859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing